

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
11 January 2001 (11.01.2001)

PCT

(10) International Publication Number
WO 01/02554 A2

(51) International Patent Classification⁷: C12N 15/10,
15/62, G01N 33/543, 33/68

KONTHUR, Zoltán (DE/DE); Stewardstr. 7, D-14167
Berlin (DE). LEHRACH, Hans (AT/DE); Terrassenstr.
31, D-14129 Berlin (DE).

(21) International Application Number: PCT/EP00/06271

(22) International Filing Date: 4 July 2000 (04.07.2000)

(74) Agent: VOSSIUS & PARTNER; Siebertstrasse 4,
D-81675 München (DE).

(25) Filing Language: English

(81) Designated States (*national*): CA, JP, US.

(26) Publication Language: English

(30) Priority Data:
99112970.1 5 July 1999 (05.07.1999) EP

(84) Designated States (*regional*): European patent (AT, BE,
CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE).

(71) Applicant (*for all designated States except US*): MAX-
PLANCK-GESELLSCHAFT ZUR FÖRDERUNG
DER WISSENSCHAFTEN E.V. (DE/DE); D-Berlin
(DE).

Published:

— Without international search report and to be republished
upon receipt of that report.

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): WALTER, Ger-
ald (DE/NO); Nedre Skogvei 14, N-0281 Oslo (NO).

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: METHOD FOR HIGH-THROUGHPUT SELECTION OF INTERACTING MOLECULES

(57) Abstract: The present invention relates to a method for the selection of at least one member of a number of specifically interacting molecules, said method being carried out in (a) container(s), preferably representing an arrayed form, e.g. in (a) microtiter plate(s), using an automated device comprising a magnetic particle processor. In another embodiment, the present invention relates to a method for the production of a pharmaceutical composition comprising the steps of the method of the present invention and further the step of formulating at least one of said specifically interacting molecules selected and/or characterized by the above method or a functionally and/or structurally equivalent derivative thereof in a pharmaceutically acceptable form.

WO 01/02554 A2